Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

GSK says it owns seven patents that “provide ... Mandl’s team discovered new formulations and methods of preparing mRNA vaccines, overcoming hurdles that had long prevented development of ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

recent lawsuits filed by GSK against mRNA vaccine producers Pfizer, BioNTech and most recently (15 October) Moderna, have put the licensing of mRNA-based pharmaceuticals in the spotlight.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...

Zoom out: GSK filed a similar lawsuit against Pfizer and BioNTech in April. The bottom line: Scientists and pharmaceutical ...

GSK (NYSE:GSK) shares fell in the morning hours in London after the British drugmaker reported ~ a 2% YoY decline in its Q3 ...